针对奥密克戎的自扩增mRNA加强疫苗用于COVID-19:一项2/3期随机试验
这项多中心开放标签随机2/3期研究评估了奥密克戎特异性自扩增mRNA疫苗GEMCOVAC-OM皮内加强接种的安全性和免疫原性。在已接种两剂BBV152或ChAdOx1 nCoV-19的健康成人中,GEMCOVAC-OM耐受良好,无相关严重不良事件;2期显示其抗刺突IgG滴度和血清转化高于原型疫苗GEMCOVAC-19,3期显示其中和抗体滴度和血清转化率非劣效且优于ChAdOx1 nCoV-19。
要点
- GEMCOVAC-OM在2期和3期均耐受良好,无相关严重不良事件。
- 2期第29天,GEMCOVAC-OM抗刺突IgG滴度和血清转化高于GEMCOVAC-19(P<0.0001)。
- 3期第29天,GEMCOVAC-OM组BA.1中和抗体滴度较基线显著升高(P<0.0001),ChAdOx1 nCoV-19组未达显著(P=0.1490)。
核心结论
- GEMCOVAC-OM安全,并增强针对B.1.1.529变异株的免疫应答。
研究设计与样本
- 多中心开放标签随机2期和3期研究,评估GEMCOVAC-OM皮内加强接种的安全性和免疫原性。
- 研究对象为已接种两剂BBV152或ChAdOx1 nCoV-19的健康成人。
- 2期在140名参与者中比较GEMCOVAC-OM与原型mRNA疫苗GEMCOVAC-19(D614G变异株特异性)。
- 3期在3140名参与者(安全性队列)中比较GEMCOVAC-OM与ChAdOx1 nCoV-19,其中包括420名参与者的免疫原性队列。
主要发现
- 2期接种后第29天,GEMCOVAC-OM组抗刺突(BA.1)IgG抗体显著升高(P<0.0001),GEMCOVAC-19组也显著升高(P<0.0001)。
- 2期GEMCOVAC-OM的IgG滴度(主要终点)和血清转化高于GEMCOVAC-19(P<0.0001)。
- 3期第29天,GEMCOVAC-OM组针对SARS-CoV-2 BA.1变异株的中和抗体滴度较基线显著升高(P<0.0001),ChAdOx1 nCoV-19组未达统计学显著(P=0.1490)。
- 3期GEMCOVAC-OM在中和抗体滴度和血清转化率方面非劣效(主要终点)且优于ChAdOx1 nCoV-19(非劣效/优效标准为最小二乘几何均值比95%置信区间下限>1且血清转化率差值>0%)。
- 3期第29天,GEMCOVAC-OM的抗刺突IgG抗体和血清转化(次要终点)显著更高(P<0.0001)。
关键数值与推荐
- 2期主要终点为IgG滴度,GEMCOVAC-OM高于GEMCOVAC-19(P<0.0001)。
- 3期主要终点为非劣效性,GEMCOVAC-OM在中和抗体滴度和血清转化率方面非劣效且优于ChAdOx1 nCoV-19。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Here we conducted a multicenter open-label, randomized phase 2 and 3 study to assess the safety and immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron-specific (BA.1/B.1.1.529), monovalent, thermostable, self-amplifying mRNA vaccine, GEMCOVAC-OM, when administered intradermally as a booster in healthy adults who had received two doses of BBV152 or ChAdOx1 nCoV-19. GEMCOVAC-OM was well tolerated with no related serious adverse events in both phase 2 and phase 3. In phase 2, the safety and immunogenicity of GEMCOVAC-OM was compared with our prototype mRNA vaccine GEMCOVAC-19 (D614G variant-specific) in 140 participants. At day 29 after vaccination, there was a significant rise in anti-spike (BA.1) IgG antibodies with GEMCOVAC-OM (P < 0.0001) and GEMCOVAC-19 (P < 0.0001). However, the IgG titers (primary endpoint) and seroconversion were higher with GEMCOVAC-OM (P < 0.0001). In phase 3, GEMCOVAC-OM was compared with ChAdOx1 nCoV-19 in 3,140 participants (safety cohort), which included an immunogenicity cohort of 420 participants. At day 29, neutralizing antibody titers against the BA.1 variant of SARS-CoV-2 were significantly higher than baseline in the GEMCOVAC-OM arm (P < 0.0001), but not in the ChAdOx1 nCoV-19 arm (P = 0.1490). GEMCOVAC-OM was noninferior (primary endpoint) and superior to ChAdOx1 nCoV-19 in terms of neutralizing antibody titers and seroconversion rate (lower bound 95% confidence interval of least square geometric mean ratio >1 and difference in seroconversion >0% for superiority). At day 29, anti-spike IgG antibodies and seroconversion (secondary endpoints) were significantly higher with GEMCOVAC-OM (P < 0.0001). These results demonstrate that GEMCOVAC-OM is safe and boosts immune responses against the B.1.1.529 variant. Clinical Trial Registry India identifier: CTRI/2022/10/046475 .
引用
- Saraf A, Gurjar R, Kaviraj S, et al. An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial. Nat Med. 2024. PMID: 38637636. doi:10.1038/s41591-024-02955-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。